Search Results
Apr 28, 2026, 10:15 ET Environmental DNA Market worth $5.61 billion by 2031- Exclusive Report by MarketsandMarkets™
(Luxembourg), SGS Société Générale de Surveillance SA (Switzerland), NatureMetrics (UK), EnviroDNA (Australia), EDNAtec (Canada), SPYGEN (France), ID-GENE ecodiagnostics Ltd. (France), Takara Bio Inc. (Japan), Stantec (Canada), Applied Genomics (UK), AllGenetics (Spain), and Jonah Ventures (US).Get
More news about: MarketsandMarkets
Apr 28, 2026, 10:00 ET ACROBiosystems Showcases AI-Driven Innovation at AACR 2026, Empowering Next-Generation Biologics Discovery
Box" Protein Engineering Toolkit autonomously optimizes multiple key properties like binding affinity, stability, and solubility. Focused on cell and gene therapy, it has been used to develop essential GMP-grade materials such as the Salt Active GENIUS™ Nuclease, Human FGF basic Superior Stable Mutant
More news about: ACROBiosystems Inc.; ACROBiosystems Group
Apr 28, 2026, 09:47 ET Lupus Research Alliance Announces New Lupus Innovation Award Recipients to Advance Understanding of Lupus
PhD, Sloan Kettering InstituteToll-like receptor (TLR7) signaling plays a major role in lupus. However, many different gene mutations – not only those affecting TLR7 – can cause lupus, and it is unclear whether a shared mechanism ties these mutations together. Dr. Gitlin
More news about: Lupus Research Alliance
Apr 28, 2026, 09:28 ET PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
disorder of the central nervous system.1 It is caused by a defective gene. This gene produces a protein, called Huntingtin (HTT), which is involved in the functioning of the nerve cells in the brain (neurons). When the gene is defective, it produces an abnormal (or mutated) HTT protein that is toxic
More news about: PTC Therapeutics, Inc.
Apr 28, 2026, 09:13 ET Introducing TIES™: A Foundational Men's Fertility and Performance Brand, Backed by $1.5M Seed Round Led by HumanCo and Jason H. Karp
Review and Network Meta-Analysis of Randomized Controlled Trials. 2022 — China Academy of Chinese Medical SciencesThe Effect of Vitamin C on the Gene Expression Profile of Sperm Protamines in the Male Partners of Couples with Recurrent Pregnancy Loss: A Randomized Clinical Trial. 2020 — Clinical and
More news about: HumanCo Investments
Apr 28, 2026, 09:05 ET Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer
clinical programs spanning rare disease, gene therapy, and cardiovascular indications. Prior to CTI, she was Senior Vice President and AAV Global Program Head at Rocket Pharmaceuticals, where she launched and led pivotal clinical programs in cardiovascular gene therapy. She previously served as Vice President
More news about: Nuevocor
Apr 28, 2026, 08:02 ET Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
dermatology, today announced the presentation of new preclinical data from its ATR-01 program at the 2026 Annual Meeting of the American Society of Gene & Cell Therapy ("ASGCT 2026").
More news about: Azitra, Inc.
Apr 28, 2026, 08:00 ET Genezen and The Charlotte & Gwenyth Gray Foundation to Cure Batten Disease Announce Manufacturing Partnership for CLN6 Gene Therapy Clinical Trial
April 28, 2026 /PRNewswire/ -- Genezen, a gene therapy contract development and manufacturing organization (CDMO), and The Charlotte & Gwenyth Gray Foundation to Cure Batten Disease today announced a manufacturing partnership to advance a CLN6 gene therapy into a Phase 1/2 clinical trial.
More news about: Genezen
Apr 28, 2026, 08:00 ET Argo Biopharma Announces First Subject Dosed in Phase I Study of siRNA Therapeutic BW-50218
BW-50218BW-50218 is an siRNA therapeutic developed from Argo Biopharma's proprietary RADS™ platform, and is designed to enable potent, durable gene silencing with differentiated safety and delivery characteristics through hepatic delivery. Argo Biopharma continues to advance a cardiovascular and
More news about: Argo Biopharmaceutical Co., Ltd
Apr 28, 2026, 07:57 ET U.S. FDA Grants Breakthrough Device Designation to Laguna Diagnostics' mRNA Gene Biomarker Test to Aid in Differentiation of Schizophrenia and Bipolar I Disorder
Diagnostics, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company's mRNA Gene Biomarker Test, a novel blood-based test designed to aid in the differentiation of schizophrenia and bipolar I disorder in symptomatic patients.
More news about: Laguna Diagnostics, LLC
Apr 28, 2026, 07:37 ET Arcera Life Sciences and Fosun Pharma launch long-term collaboration framework
foster sovereign R&D capabilities in the UAE across small molecules, biologics, radiopharmaceuticals, small interfering RNA therapies, and cell and gene therapies.Strategic collaboration in neuroscience: The neuroscience collaboration will focus particularly on neurodegenerative diseases,
More news about: Fosun Pharma
Apr 28, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present positive preclinical data on the Company's diabetes gene therapy drug candidate at the upcoming 2026 American Society of Gene and
More news about: Genprex, Inc.
Apr 28, 2026, 07:00 ET Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting
treat human diseases by rewriting RNA, today announced it will present two oral presentations and one poster presentation at the American Society of Gene & Cell Therapy (ASGCT) annual meeting in Boston, MA, May 11-15, 2026.
More news about: Ascidian Therapeutics
Apr 28, 2026, 07:00 ET Triquetra Health Launches BioActive B-Complex™ Liquid--First Formula with Five Active B-Vitamin Form Upgrades and Tri-Form B12 in Liquid Delivery
folate form, requires the MTHFR enzyme to convert to active L-5-MTHF before the methylation cycle can use it. An estimated 40–60% of adults carry MTHFR gene variants that reduce this enzyme's activity by 35–70%. Meanwhile, standard thiamine HCl relies on saturable carrier proteins that limit tissue delivery
More news about: Triquetra Health LLC
Apr 28, 2026, 06:00 ET Economic Pressure Makes Boomerang Living a New Normal, Annual Thrivent Survey Finds
"Adult children moving back in with their parents has shifted from stigma to strategy – for both parents and kids," says Thrivent Financial Consultant Gene Elder. "Five years into Thrivent's survey, we've found that boomerang living is not a blip; it's becoming a lasting part of how families plan their
More news about: Thrivent
Apr 28, 2026, 04:07 ET Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
Class I recommendation.First-line treatment for advanced driver gene-negative squamous NSCLC with PD-L1 TPS ≥1%: Ivonescimab monotherapy upgraded to Class I recommendation.First-line treatment for advanced driver gene-negative non-squamous NSCLC with PD-L1 TPS ≥1%: Ivonescimab monotherapy
More news about: Akeso, Inc.
Apr 27, 2026, 16:30 ET Apertura Gene Therapy and Scientists from the Broad Institute to Share Data on TfR1 CapX™, a Novel Capsid Targeting the Central Nervous System (CNS), at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Science.About Apertura Gene Therapy Apertura Gene Therapy develops genetic medicines and next-generation AAV capsids that engage human-relevant receptors, aiming to enable more effective and selective gene delivery. The company's lead capsid, TfR1 CapX™, leverages human
More news about: Apertura Gene Therapy
Apr 27, 2026, 11:30 ET Avirmax Biopharma Inc. Proudly Presents at the 2026 ARVO Annual Meeting in Denver, Colorado
Session Title: Gene Editing and Gene Therapy II Session Date/Time: May 5, 2026, from 8:30 AM to 10:15 AM MDTDr. Shengjiang Liu, Ph.D. Chief Executive and Scientific Officer will present "From Bench to Clinic: CMC and Preclinical Development of ABI-110 Gene Therapy for Ocular Neovascularized
More news about: Avirmax
Apr 27, 2026, 08:44 ET BioMarin Completes Acquisition of Amicus Therapeutics
pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable galactosidase alpha gene (GLA) variants. In these patients, Galafold works by stabilizing the body's own dysfunctional enzyme so that it can clear the accumulation of disease
More news about: BioMarin Pharmaceutical Inc.
Apr 27, 2026, 08:30 ET Greenland Mines Appoints SLR Consulting as Geological Consultant and Qualified Person for Skaergaard
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80%
More news about: Greenland Mines Ltd
Apr 27, 2026, 08:00 ET Avista Therapeutics Announces Presentations at Upcoming Medical Meetings
Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, today announced the participation of Dr. Rob Lin, Chief Executive Officer, in a corporate presentation at the 2026 Cell & Gene Meeting on the Mediterranean being held April
More news about: Avista Therapeutics
Apr 27, 2026, 07:45 ET Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
metastatic GEA. The FDA granted two Breakthrough Therapy designations for zanidatamab's development: one as a single agent for previously treated HER2 gene-amplified BTC, and one in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab for first-line HER2+
More news about: Jazz Pharmaceuticals plc
Apr 27, 2026, 05:00 ET Perceptive eClinical Launches Technology-Enabled Clinical Supply Consultancy in Alliance with Trialzen
experience across Endocrinology and Metabolism, and Infectious Diseases, and supports emerging areas such as Precision and Nuclear Medicine, and Cell and Gene Therapies. Reflecting on this alliance and its objectives, Cedric Druck, CEO and Co–Founder of Trialzen, commented: "Trialzen was built by clinical
More news about: Perceptive eClinical Ltd
Apr 27, 2026, 05:00 ET Perceptive eClinical Launches Technology-Enabled Clinical Supply Consultancy in Alliance with Trialzen
experience across Endocrinology and Metabolism, and Infectious Diseases, and supports emerging areas such as Precision and Nuclear Medicine, and Cell and Gene Therapies. Reflecting on this alliance and its objectives, Cedric Druck, CEO and Co–Founder of Trialzen, commented: "Trialzen was built by clinical
More news about: Perceptive eClinical Ltd
Apr 24, 2026, 09:00 ET Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
ISM0387 lies in synthetic lethality, a specific relationship between two genes (known as a synthetic lethal pair) where a mutation or deficiency in either gene alone allows the cell to survive, but the loss of both genes simultaneously is fatal. As a result, the inhibition of Protein Arginine Methyltransferase
More news about: Insilico Medicine